What Is Semaglutide?

Semaglutide is a peptide analogue of human glucagon-like peptide-1 (GLP-1) and is classified as a GLP-1 receptor agonist.

The compound has become one of the most extensively studied GLP-1-based molecules in metabolic research, with research spanning glucose regulation, appetite-related pathways, body-weight regulation, cardiovascular outcomes and other metabolic conditions.

According to FDA prescribing information, semaglutide has approximately 94% sequence homology with human GLP-1 and selectively binds to and activates the GLP-1 receptor.

For researchers, understanding semaglutide begins with understanding the biology of the GLP-1 receptor.

What Is the GLP-1 Receptor?

The GLP-1 receptor (GLP-1R) is a receptor activated naturally by the hormone GLP-1.

GLP-1 is involved in several physiological processes, including glucose regulation, insulin secretion, glucagon regulation, gastrointestinal activity and appetite-related signalling.

Semaglutide is designed to activate this receptor and reproduce important aspects of endogenous GLP-1 signalling while having a substantially longer duration of activity.

This receptor-specific activity is the foundation of semaglutide research.

How Does Semaglutide Work?

Semaglutide selectively activates the GLP-1 receptor.

According to FDA clinical pharmacology information, GLP-1 receptor activation by semaglutide contributes to glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion. Semaglutide can also delay gastric emptying, particularly during the early post-meal period.

The simplified pathway can be represented as:

Semaglutide → GLP-1 receptor activation → metabolic signalling

Researchers commonly investigate several downstream effects of this signalling, including:

• glucose regulation;
• insulin secretion;
• glucagon suppression;
• appetite-related signalling;
• gastric-emptying effects;
• body-weight regulation;
• cardiovascular outcomes.

Why Is Semaglutide Different From Natural GLP-1?

Natural GLP-1 is rapidly degraded in the body.

Semaglutide was engineered to remain active for substantially longer.

One important feature is its ability to bind albumin. FDA documentation explains that albumin binding contributes to semaglutide’s prolonged pharmacological activity by reducing renal clearance and protecting the molecule from metabolic degradation. Semaglutide is also stabilised against degradation by the DPP-4 enzyme.

This molecular engineering is an important part of the scientific story behind semaglutide.

Novo Nordisk’s research history describes how scientists worked to develop a GLP-1 analogue capable of providing much longer activity than naturally occurring GLP-1.

Semaglutide and GLP-1 Receptor Activity

The GLP-1 receptor is central to semaglutide’s pharmacological profile.

When activated, GLP-1 receptor signalling can influence several physiological systems.

Pancreatic Signalling

GLP-1 receptor activation can increase insulin secretion in a glucose-dependent manner.

This means the response is linked to circulating glucose levels rather than simply producing continuous insulin stimulation.

Glucagon Regulation

Semaglutide can reduce glucagon secretion in a glucose-dependent manner.

Glucagon is an important hormone involved in glucose homeostasis, making this pathway another major area of GLP-1 research.

Appetite-Related Signalling

GLP-1 receptor activity also involves areas of the central nervous system associated with appetite regulation.

FDA information for Wegovy states that the GLP-1 receptor is present in brain regions involved in appetite regulation and that semaglutide decreases calorie intake, with effects likely mediated partly through appetite.

Gastric Emptying

Semaglutide can delay gastric emptying.

This represents another component of GLP-1 receptor pharmacology and is an important consideration when studying the broader physiological effects of GLP-1 receptor agonism.

Semaglutide Research Areas

Semaglutide has been investigated across a broad range of research areas.

1. Glucose Regulation

Research has examined semaglutide’s effects on fasting and post-meal glucose concentrations and glucose-dependent insulin secretion.

2. Obesity and Body-Weight Research

Semaglutide has been extensively studied in obesity and body-weight research.

Clinical programmes have evaluated different semaglutide formulations and doses in people with overweight or obesity.

3. Cardiovascular Research

Semaglutide research has expanded beyond glucose and body weight.

The SELECT programme investigated cardiovascular outcomes in people with overweight or obesity who did not have diabetes, while more recent research continues to examine cardiovascular and metabolic effects.

4. Kidney Research

Semaglutide has also been studied in chronic kidney disease and diabetes-related kidney research.

5. Liver Research

More recent clinical research has examined semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) and related liver outcomes. Current FDA prescribing information includes an accelerated-approval indication for Wegovy in adults with noncirrhotic MASH with moderate to advanced fibrosis.

Semaglutide Clinical Research

Semaglutide has an extensive clinical-development history.

Research programmes have investigated different formulations, populations and therapeutic endpoints.

More recent research continues to expand the scientific understanding of semaglutide.

For example, the STEP UP programme investigated higher-dose semaglutide in adults with obesity. Novo Nordisk reported that semaglutide 7.2 mg produced greater average weight reduction than the 2.4 mg comparison group in the 72-week trial. These findings are clinical-trial results, not evidence that research-use products should be used in humans.

Research presented in 2026 has also continued examining semaglutide’s cardiovascular and metabolic effects.

Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are sometimes grouped together because both are important metabolic peptide medicines, but their receptor profiles are different.

Semaglutide

GLP-1 receptor agonist

Tirzepatide

GIP + GLP-1 receptor agonist

Therefore, semaglutide represents a primarily GLP-1-based mechanism, while tirzepatide adds GIP receptor activity.

This difference is particularly useful when studying the evolution of incretin-based pharmacology.

Semaglutide vs Retatrutide

The distinction becomes even greater when semaglutide is compared with retatrutide.

Semaglutide

GLP-1

Retatrutide

GIP + GLP-1 + glucagon

Retatrutide, also known as LY3437943, remains investigational, while semaglutide has approved pharmaceutical products for specific indications.

Therefore, these compounds should not be presented as equivalent products.

Is Semaglutide a GLP-1 Receptor Agonist?

Yes.

Semaglutide is specifically classified as a GLP-1 receptor agonist.

The FDA describes semaglutide as a GLP-1 analogue that selectively binds to and activates the GLP-1 receptor.

This is the central mechanism behind semaglutide’s pharmacological activity.

Why Is Semaglutide Important in Peptide Research?

Semaglutide is particularly significant because it demonstrates how peptide engineering can modify the pharmacological characteristics of a naturally occurring hormone.

Researchers have studied how modifications to the GLP-1 structure can:

• improve molecular stability;
• extend biological activity;
• influence receptor signalling;
• alter pharmacokinetic properties;
• enable practical pharmaceutical formulations.

The development of semaglutide also helped demonstrate the broader potential of GLP-1-based therapeutic research.

Semaglutide Research and Oral Formulations

Semaglutide is notable because it has been developed in both injectable and oral pharmaceutical formulations.

Developing an oral peptide is technically challenging because proteins and peptides can be degraded or poorly absorbed within the gastrointestinal tract.

Novo Nordisk describes the development of oral semaglutide as a major peptide-engineering achievement, involving molecular stabilisation and the use of SNAC to facilitate absorption.

This makes oral semaglutide an important example of pharmaceutical peptide-delivery research.

What Makes Semaglutide a Useful Research Model?

Semaglutide provides researchers with an established model for studying GLP-1 receptor agonism.

Its research relevance includes:

• receptor pharmacology;
• incretin biology;
• glucose metabolism;
• appetite signalling;
• body-weight regulation;
• cardiovascular research;
• metabolic disease;
• peptide engineering;
• oral peptide delivery.

Consequently, semaglutide is relevant not only to metabolic research but also to broader peptide-development research.

Semaglutide Research Quality Considerations

When evaluating semaglutide-related research materials, researchers should distinguish between:

Approved pharmaceutical products

and

laboratory research materials marketed for research use.

These categories are not interchangeable.

Researchers should consider documentation such as:

• product identity;
• batch or lot information;
• certificate of analysis;
• analytical testing;
• stated purity;
• storage information;
• manufacturer documentation.

A product described as a research material should not automatically be assumed to have the same quality, formulation or regulatory status as an approved pharmaceutical product.

Semaglutide Regulatory Status

Semaglutide is substantially different from investigational compounds such as retatrutide because semaglutide-containing medicines have received regulatory approvals for specific indications.

The FDA’s current 2026 Wegovy prescribing information identifies semaglutide as a GLP-1 receptor agonist and lists approved indications including certain weight-management, cardiovascular-risk and MASH uses.

However, approval applies to specific pharmaceutical products, formulations and indications. It should not be interpreted as blanket approval for every semaglutide-containing product sold online or marketed as a research material.

The Future of Semaglutide Research

Semaglutide research continues to expand beyond its original focus on glucose regulation.

Current research areas include:

• obesity;
• cardiovascular disease;
• kidney disease;
• MASH;
• appetite regulation;
• higher-dose formulations;
• oral delivery;
• combination therapies;
• next-generation GLP-1 approaches.

The continuing development of GLP-1-based medicines also provides a foundation for investigating more complex multi-receptor compounds.

This helps explain why semaglutide is frequently compared with newer compounds such as tirzepatide and investigational retatrutide.

Frequently Asked Questions

What is semaglutide?

Semaglutide is a GLP-1 analogue and GLP-1 receptor agonist that has been extensively studied in metabolic research.

What does semaglutide target?

Semaglutide selectively activates the GLP-1 receptor.

What is GLP-1 receptor activity?

GLP-1 receptor activity involves signalling pathways associated with glucose regulation, insulin secretion, glucagon regulation, gastrointestinal activity and appetite-related processes.

Is semaglutide a peptide?

Yes. Semaglutide is a peptide analogue of human GLP-1.

What is the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.

What is the difference between semaglutide and retatrutide?

Semaglutide primarily targets GLP-1 receptors. Retatrutide is an investigational compound being studied for activity at GIP, GLP-1 and glucagon receptors.

Is semaglutide approved?

Specific semaglutide pharmaceutical products have regulatory approval for specified indications. Approval does not apply universally to every semaglutide product or research material.

Why is semaglutide important in peptide research?

Semaglutide provides an important example of how peptide engineering can extend the activity and pharmaceutical usability of a naturally occurring hormone analogue.

Conclusion

Semaglutide remains one of the most important compounds in modern GLP-1 receptor research.

Its selective GLP-1 receptor activity has enabled extensive research into glucose regulation, appetite-related signalling, body-weight regulation and broader cardiometabolic outcomes.

From a research perspective, semaglutide also represents an important stage in the development of peptide pharmacology:

GLP-1 receptor agonism → dual GIP/GLP-1 agonism → emerging multi-receptor approaches.

Understanding semaglutide therefore provides valuable scientific context for studying newer compounds such as tirzepatide and investigational retatrutide.

Research Use Only: This article is provided for educational and scientific research information. It does not provide medical advice, diagnosis, treatment recommendations, dosing instructions or recommendations for human use. Researchers should independently verify product documentation, regulatory status and applicable laboratory requirements.